Cite

HARVARD Citation

    Tijeras-Raballand, A. et al. (n.d.). Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC). European journal of cancer. pp. S133-. [Online]. 
  
Back to record